The University of Cambridge, founded in 1209, is a prestigious public research university located in Cambridge, United Kingdom. It is organized into 31 colleges and 150 departments, encompassing six schools: Arts and Humanities, Biological Sciences, Clinical Medicine, Humanities and Social Sciences, Physical Sciences, and Technology. With a diverse community of over 20,000 students and 12,000 staff members from around the globe, the university offers a wide range of undergraduate, graduate, and postgraduate programs across various disciplines, including humanities, sciences, law, and engineering. In addition to its educational offerings, the university is renowned for its extensive research activities, which span fields such as clinical medicine, biomedicine, and engineering. The institution also manages museums, libraries, and collections, and actively commercializes intellectual properties developed within its academic framework. The University of Cambridge is recognized as one of the world's leading academic institutions, noted for its historical significance, outstanding academic achievements, and contributions to research and knowledge.
Robin AI is a legal technology startup focused on automating legal processes through artificial intelligence. Its software enhances the contract mark-up process by providing essential features while ensuring enterprise-grade encryption and security, which helps safeguard sensitive data. The platform empowers legal teams to delegate low-complexity tasks, thereby simplifying and streamlining legal workflows. By automating routine aspects of legal work, Robin AI enables professionals to concentrate on more complex and high-value tasks, ultimately improving productivity and efficiency within legal practices.
Xwatts
Pre Seed Round in 2024
Xwatts is a developer of intelligent energy management software aimed at helping commercial buildings minimize costs and reduce emissions. The company's system continuously analyzes usage patterns, environmental conditions, and market data to optimize electricity consumption. By providing building owners with the tools to take direct control of their distributed energy assets, Xwatts enables the integration of historical usage data with real-time market insights. This functionality allows building management systems to effectively evaluate and schedule energy assets, ultimately leading to significant reductions in electricity consumption costs.
Wave Photonics
Seed Round in 2024
Wave Photonics is a company based in Cambridge, UK, that focuses on advancing integrated photonics design through computational techniques. It develops a platform aimed at optimizing product designs and facilitating smoother integration within the supply chain. This platform includes a software tool that predicts the performance and variability of photonic components based on specific fabrication processes, along with an optimizer that creates a component library tailored for different manufacturing foundries. By streamlining these processes, Wave Photonics enables businesses to enhance efficiency in the development and production of integrated photonics products, ultimately promoting wider adoption of these technologies.
Echion Technologies
Series B in 2024
Echion Technologies Ltd. is a company based in Cambridge, United Kingdom, founded in 2017, that specializes in the development and manufacturing of advanced materials for lithium-ion batteries. The company focuses on producing optimized anode materials, notably its proprietary XNO® material, which enhances charging speed, extends battery lifespan, and improves safety compared to conventional options. Echion aims to serve the mobile device and automotive industries, particularly targeting the heavy-duty electric vehicle market. By offering cost-effective battery electrode materials, Echion strives to promote sustainable electrification and improve efficiency within the transportation sector.
Zetta Genomics
Seed Round in 2024
Zetta Genomics is a Cambridge-based company established in 2018 that focuses on managing large-scale genomic data to advance precision medicine. The company operates a user-centric platform that facilitates connections between individuals and researchers, allowing users to opt in or out of studies related to various health conditions, including common disorders like eczema and diabetes, as well as rare diseases such as muscular dystrophy. By employing distributed database technology and robust security measures, Zetta Genomics ensures the privacy of genomic data while enabling scientists to access dynamic health and genetic datasets for personalized medicine research. The platform emphasizes transparency and control for users throughout the data-sharing process.
Xampla
Series B in 2024
Xampla Ltd is a cleantech company based in Cambridge, United Kingdom, that specializes in developing plant protein-based materials as sustainable alternatives to traditional plastics and microplastics. Founded in 2018, Xampla produces a variety of products, including microcapsules, films, coatings, and beads, which are designed for use in sectors such as food, cosmetics, household products, animal feed, packaging, and medical applications. All materials are biodegradable and biocompatible, made without synthetic ingredients, allowing clients to create environmentally friendly products that minimize pollution.
T-Therapeutics
Series A in 2023
T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.
Nu Quantum
Seed Round in 2023
Nu Quantum Ltd is a company focused on developing quantum photonics hardware and infrastructure essential for scaling quantum computers. Founded in 2018 and based in Cambridge, United Kingdom, the company specializes in creating solutions that interconnect quantum computing cores into large distributed clusters. Its offerings include photon sources and detectors, as well as systems for quantum cryptography that enable secure key exchanges. Nu Quantum is also engaged in producing nano-engineered materials that facilitate light generation at the quantum level and ultra-sensitive light detection. By partnering with leading quantum computing companies, governments, and research institutions, Nu Quantum aims to advance the development of entangled qubit networks and accelerate the creation of multi-core quantum supercomputers and quantum data centers.
Materials Nexus
Seed Round in 2023
Materials Nexus is a deep-tech company focused on advancing sustainable materials through an innovative material modeling platform. By automating quantum calculations, the company enhances the accuracy of material research at scale, thereby facilitating the development of green materials that contribute to net-zero emissions. Utilizing insights from quantum mechanics and artificial intelligence, Materials Nexus aims to reduce greenhouse gas emissions in the materials sector, providing clients with access to sustainable building solutions. Through its efforts, the company seeks to accelerate the transition to environmentally friendly materials and support the global shift toward sustainability.
RoboK
Seed Round in 2023
RoboK is a computer vision startup based in Cambridge, United Kingdom, founded in 2017. The company specializes in designing and developing simultaneous localization and mapping (SLAM) algorithms and advanced 3D sensing technologies tailored for automotive and industrial applications, including autonomous driving and machine automation. RoboK focuses on enhancing safety and performance in industrial workplaces through innovative, privacy-preserving technology that optimizes the capabilities of existing CCTV systems. By transforming visual data from large-scale transport and logistics infrastructures into actionable insights, RoboK collaborates with major operators in critical sectors to deliver enhanced object detection, classification, and tracking. The company aims to maximize the value of visual data, turning passive surveillance systems into proactive tools for efficiency and safety.
Planetary Processing
Pre Seed Round in 2023
Planetary Processing provides an SDK for the creation and operation of massively-multiplayer online games. Simplifying the creation and maintenance of large online games allows game studios to focus on game development instead of infrastructure.
PharmEnable
Seed Round in 2023
PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that was incorporated in 2016. The company specializes in using medicinal chemistry and artificial intelligence to design small molecule drugs. PharmEnable has developed a rapid and cost-effective method for identifying improved chemical starting points, which aims to enhance the discovery of essential new medicines.
Zetta Genomics
Seed Round in 2023
Zetta Genomics is a Cambridge-based company established in 2018 that focuses on managing large-scale genomic data to advance precision medicine. The company operates a user-centric platform that facilitates connections between individuals and researchers, allowing users to opt in or out of studies related to various health conditions, including common disorders like eczema and diabetes, as well as rare diseases such as muscular dystrophy. By employing distributed database technology and robust security measures, Zetta Genomics ensures the privacy of genomic data while enabling scientists to access dynamic health and genetic datasets for personalized medicine research. The platform emphasizes transparency and control for users throughout the data-sharing process.
Seprify
Seed Round in 2023
Seprify is a manufacturer specializing in cellulose-based products aimed at promoting sustainability within various industries. The company develops plant-based cellulose white pigments and opacifier solutions designed to serve as alternatives to traditional titanium dioxide. These pigments are derived from renewable materials that are cost-effective, biocompatible, and easily processed, allowing for scalability using established industrial methods. Seprify's offerings cater to a range of sectors, including paints, inks, cosmetics, pharmaceuticals, and food, enabling businesses to create safer and more sustainable products. By focusing on cellulose-based solutions, Seprify supports the transition toward a circular economy and encourages the adoption of environmentally friendly practices among its clients.
52 North
Seed Round in 2023
52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.
Kalium Health
Venture Round in 2022
Kalium Health Ltd is a company focused on improving kidney care through innovative medical technology. Based in Cambridge, United Kingdom, it designs and manufactures a finger-prick blood test specifically for measuring blood potassium concentration. This test aims to facilitate early treatment for patients, reducing the complications and costs associated with traditional testing methods. By leveraging advanced electrolyte sensing technology, Kalium Health provides patients with accurate, real-time data essential for managing cardiorenal diseases. The company’s first product addresses a significant risk in kidney disease, a condition that imposes substantial financial burdens on healthcare systems. With a clear regulatory pathway and a targeted market strategy, Kalium Health is poised to transform patient care and enhance outcomes for millions affected by kidney disease.
Carbon Re
Seed Round in 2022
Carbon Re is a climate technology company focused on utilizing artificial intelligence to decarbonize energy-intensive industries such as cement, steel, and glass, which collectively contribute over 20% of global carbon emissions. The company has developed the Delta Zero platform, which leverages deep learning to facilitate the rapid development and implementation of low-carbon industrial processes, designs, and materials. By merging continuous improvement techniques with AI, Carbon Re's cloud-based platform aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions, electricity consumption, and fuel costs in manufacturing. This innovative approach positions Carbon Re as a key player in the effort to drive substantial reductions in carbon emissions across foundational industries.
Pretzel Therapeutics
Series A in 2022
Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.
CardiaTec Biosciences
Pre Seed Round in 2022
CardiaTec is a digital biotechnology company focused on revolutionizing cardiovascular drug discovery through the integration of artificial intelligence and specialized expertise. The company aims to transform the understanding of cardiovascular disease by developing AI-driven platforms for target identification and novel drug discovery. This approach seeks to provide effective therapeutics for cardiovascular diseases, addressing significant gaps in diagnostics, patient stratification, and treatment options for conditions such as coronary artery disease. By leveraging advanced technology and scientific knowledge, CardiaTec is dedicated to improving healthcare outcomes related to cardiovascular health.
Spirea
Venture Round in 2022
Spirea Ltd. is a healthcare technology company based in Harrogate, United Kingdom, that specializes in developing antibody drug conjugates (ADCs) for cancer treatment. Founded in 2015, Spirea has created a smart polymer platform designed for the controlled delivery of drug combinations, thereby maximizing the clinical efficacy of therapies. The company's innovative approach to ADCs allows for a greater amount of drug payload to be specifically targeted to tumor cells, resulting in enhanced therapeutic effects while significantly minimizing side effects. This development enables healthcare providers to offer well-tolerated treatment options for a variety of cancers, ultimately aiming to improve the quality of life for patients.
Colorifix
Series B in 2022
Colorifix Limited is a biotechnology company based in Norwich, United Kingdom, that specializes in innovative textile dyeing services using entirely biological methods. Founded in 2015, Colorifix has developed a unique approach to produce, deposit, and fix pigments onto textiles through synthetic biology. This process utilizes natural colorants derived from organisms such as microbes, plants, and insects, as well as agricultural by-products like sugar molasses, to create safe and environmentally friendly dyes. By eliminating harsh chemicals commonly used in traditional dyeing processes, Colorifix significantly reduces water consumption and pollution, contributing to a more sustainable textile industry. The company’s technological advancements have attracted investment from various stakeholders, supporting its ongoing expansion efforts.
Concr
Seed Round in 2022
Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.
52 North
Seed Round in 2022
52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.
Regulatory Genome
Seed Round in 2022
Regulatory Genome provides dynamic, granular, and interoperable machine-readable regulatory content powered by AI-based textual information extraction techniques. Regulatory Genome enables regulatory authorities to improve the accessibility and dissemination of regulatory information, while also enabling organizations to deepen their regulatory intelligence and digitize their compliance and risk management processes. RegGenome content is vendor-neutral, allowing it to be integrated into any application or system, allowing for the creation of an efficient ecosystem of providers and users.
Tenyks
Seed Round in 2022
Tenyks is a spin-out from the University of Cambridge focused on enhancing the interaction between humanity and artificial intelligence, particularly in the realm of computer vision. The company has developed a monitoring and validation platform aimed at machine learning engineers, enabling them to build more reliable software swiftly. Through this platform, users can validate, test, and monitor model behavior, identify common failure patterns, and understand the reasons behind shifts in data distribution. Tenyks’ technology is grounded in extensive research in Explainable AI, comprising contributions from two PhD and one Master theses, which underpins its capability to reduce the amount of labeled data needed for high-performance outcomes. This approach allows AI developers to address algorithmic issues efficiently, thereby accelerating the development of robust machine learning operations.
BKwai
Seed Round in 2022
BKwai specializes in providing engineers with advanced insights through a software platform that enhances infrastructure asset management across its lifecycle. By harnessing data from on-site sensors and satellite imagery, BKwai utilizes artificial intelligence and structural engineering principles to monitor the health of infrastructure. This approach aims to optimize the use of site data, ultimately making infrastructure operate more intelligently, efficiently, and safely. The company's mission focuses on unlocking the full potential of data to support a more resilient built environment, addressing the often-overlooked aspects of construction and asset management.
Semarion
Seed Round in 2022
Semarion is a spin-out from the Cavendish Laboratory at the University of Cambridge, specializing in drug discovery and cell microcarrier technology. The company aims to enhance the process of drug screening by utilizing innovative materials and techniques from the microchip industry combined with cell biology. Its platform features ultra-miniaturized, magnetically steerable microcarriers designed to support small colonies of cells, which facilitates advanced assaying workflows and new experimental approaches. This technology is particularly focused on identifying GPCR-targeting oncology drugs, addressing significant gaps in medical needs and accelerating the pace of drug development.
Signaloid
Pre Seed Round in 2022
Signaloid is a technology company that offers a cloud-based computing platform designed to track uncertainties in data inputs and their effects on software outputs. Its advanced hardware and software technologies cater to a range of applications, including materials modeling, autonomous systems, computational finance, machine learning, and quantum computing. By providing tools that allow clients to assess the quality of decisions made through algorithms and data, Signaloid helps organizations meet regulatory requirements, optimize costs, and enhance safety outcomes.
Barocal
Seed Round in 2022
Barocal specializes in innovative cooling technology aimed at addressing low-carbon refrigeration needs. The company has developed a system that utilizes materials capable of significant thermal changes when pressure is applied or removed. This unique approach enhances energy efficiency while ensuring a zero greenhouse warming impact, particularly in the commercial food and drink refrigeration sector. By implementing Barocal's technology, clients can effectively reduce their indirect emissions of greenhouse gases, contributing to a more sustainable environment.
Zetta Genomics
Seed Round in 2022
Zetta Genomics is a Cambridge-based company established in 2018 that focuses on managing large-scale genomic data to advance precision medicine. The company operates a user-centric platform that facilitates connections between individuals and researchers, allowing users to opt in or out of studies related to various health conditions, including common disorders like eczema and diabetes, as well as rare diseases such as muscular dystrophy. By employing distributed database technology and robust security measures, Zetta Genomics ensures the privacy of genomic data while enabling scientists to access dynamic health and genetic datasets for personalized medicine research. The platform emphasizes transparency and control for users throughout the data-sharing process.
Carbon Re
Pre Seed Round in 2021
Carbon Re is a climate technology company focused on utilizing artificial intelligence to decarbonize energy-intensive industries such as cement, steel, and glass, which collectively contribute over 20% of global carbon emissions. The company has developed the Delta Zero platform, which leverages deep learning to facilitate the rapid development and implementation of low-carbon industrial processes, designs, and materials. By merging continuous improvement techniques with AI, Carbon Re's cloud-based platform aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions, electricity consumption, and fuel costs in manufacturing. This innovative approach positions Carbon Re as a key player in the effort to drive substantial reductions in carbon emissions across foundational industries.
Wave Photonics
Pre Seed Round in 2021
Wave Photonics is a company based in Cambridge, UK, that focuses on advancing integrated photonics design through computational techniques. It develops a platform aimed at optimizing product designs and facilitating smoother integration within the supply chain. This platform includes a software tool that predicts the performance and variability of photonic components based on specific fabrication processes, along with an optimizer that creates a component library tailored for different manufacturing foundries. By streamlining these processes, Wave Photonics enables businesses to enhance efficiency in the development and production of integrated photonics products, ultimately promoting wider adoption of these technologies.
Echion Technologies
Series A in 2021
Echion Technologies Ltd. is a company based in Cambridge, United Kingdom, founded in 2017, that specializes in the development and manufacturing of advanced materials for lithium-ion batteries. The company focuses on producing optimized anode materials, notably its proprietary XNO® material, which enhances charging speed, extends battery lifespan, and improves safety compared to conventional options. Echion aims to serve the mobile device and automotive industries, particularly targeting the heavy-duty electric vehicle market. By offering cost-effective battery electrode materials, Echion strives to promote sustainable electrification and improve efficiency within the transportation sector.
Porotech
Venture Round in 2021
Porotech is a spin-out from the University of Cambridge that specializes in the development of gallium nitride (GaN) semiconductor technologies. Co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver, the company focuses on creating energy-efficient wide-bandgap semiconductors through advanced material technologies. By harnessing the potential of GaN, Porotech aims to enhance the efficiency of light-emitting diodes and various electronic devices, thereby contributing to innovations in the electronics industry.
Porotech
Seed Round in 2021
Porotech is a spin-out from the University of Cambridge that specializes in the development of gallium nitride (GaN) semiconductor technologies. Co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver, the company focuses on creating energy-efficient wide-bandgap semiconductors through advanced material technologies. By harnessing the potential of GaN, Porotech aims to enhance the efficiency of light-emitting diodes and various electronic devices, thereby contributing to innovations in the electronics industry.
iKVA
Seed Round in 2021
iKVA is a company that specializes in AI-powered knowledge management solutions. Its platform is designed to help organizations discover and transform data into actionable business insights. By employing machine learning, natural language processing, and semantic technology, iKVA indexes unstructured data from various sources, such as document archives, emails, chats, and videos. This capability significantly reduces the time businesses spend searching for information and mitigates risks by ensuring that the correct information is readily available.
Abselion
Seed Round in 2021
Abselion specializes in the development of biological sensors aimed at the rapid and cost-effective detection of various biological substances, including proteins, DNA, and small molecules. The company's innovative diagnostic analyzers and kits simplify the analysis of these biomolecules, making them valuable tools for pharmaceutical research and manufacturing. By enabling researchers to conduct sensitive, rapid, and near real-time medical diagnoses, Abselion enhances the understanding of biomolecular interactions, particularly in protein interaction analysis. This focus on efficiency and accuracy positions Abselion as a key player in the field of biosensing technology.
Concr
Pre Seed Round in 2021
Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.
Nyobolt
Series A in 2021
Nyobolt is a developer of advanced battery technology focused on automotive applications. Founded in 2020 and based in Cambridge, United Kingdom, the company specializes in creating batteries that offer high power, rapid charging capabilities, and substantial energy storage. By utilizing innovative materials, efficient cell designs, and sophisticated software control, Nyobolt aims to provide the automotive industry with solutions tailored for high-power usage. Its research and development efforts are directed toward enhancing battery performance to meet the growing demands of electric vehicles and other automotive technologies.
Cambridge GaN Devices
Series A in 2021
Cambridge GaN Devices specializes in the development and commercialization of gallium nitride (GaN) power devices aimed at improving energy efficiency in electronic applications. The company offers a variety of GaN-based semiconductor products that enhance power conversion and minimize energy loss across different systems. These advanced devices find applications in sectors such as renewable energy, electric vehicles, and consumer electronics, supporting the shift towards more sustainable technologies. Cambridge GaN Devices focuses on creating transistors that are faster, more compact, and more efficient than traditional silicon alternatives, thereby enabling industries to utilize tailored semiconductors for critical applications. The company collaborates with industry partners to promote innovation and facilitate the integration of its technology into the power semiconductor market.
NiftPad
Pre Seed Round in 2021
NiftPad is a platform that allows brands to create and sell unique digital assets without requiring any coding skills. Founded in October 2021 as a spin-off from the University of Cambridge, NiftPad offers a white-label shop solution that enables enterprises to launch non-fungible token projects with ease. The platform provides businesses with the tools to build fully customizable online stores, facilitating the issuance and sale of digital assets. This innovative approach helps brands diversify their revenue streams and engage with their communities in novel ways, making digital asset management accessible to a wider range of enterprises. NiftPad is backed by notable investors, including Animoca Brands and Brinc.
Sano Genetics
Seed Round in 2021
Sano Genetics Limited is a health technology company based in Cambridge, United Kingdom, that operates a user-centric genetic data-sharing platform. Founded in 2017, the company enables individuals to contribute their genetic and health data for research purposes, thereby advancing personalized medicine and scientific understanding. It provides researchers with tools to analyze user-consented data, facilitating recruitment for studies and clinical trials. The platform supports research on a variety of genetic conditions and human traits, including common disorders such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. By allowing participants to share their genetic information, Sano Genetics aims to enhance the development of new treatments and cures in the field of medicine.
Riverlane
Series A in 2021
Riverlane is a business focused on developing quantum computing software and engineering instruments to enhance the performance of quantum computers. The company collaborates with quantum computer manufacturers to create essential hardware and software tools that address the challenges posed by unstable qubits and system defects. By designing an ultra-low latency quantum operating system, Riverlane accelerates quantum-classical hybrid algorithms, thereby advancing hardware research and development. Their algorithms are specifically engineered to optimize the utilization of the complete quantum computing stack, helping hardware partners mitigate the system errors that currently hinder the effectiveness of quantum computers. Through these innovative solutions, Riverlane aims to transform experimental quantum technologies into viable commercial products.
8Power
Series A in 2020
8Power Limited specializes in the manufacturing of autonomous sensor systems tailored for various sectors, including automotive, transportation, civil engineering, industrial equipment, and utility infrastructure. The company has developed wireless sensor technology that provides real-time condition monitoring data and analytics for industrial applications. This technology enables clients to monitor the performance of their assets, such as pumps, motors, and gearboxes, across numerous remote locations. By offering a cost-effective solution, 8Power facilitates easy installation and effective machine condition monitoring, serving industries such as water and waste treatment, manufacturing, and oil and gas.
Sorex Sensors
Seed Round in 2020
Sorex Sensors Limited specializes in the design and manufacture of film bulk acoustic resonator (FBAR) technology-based micro-electro-mechanical system (MEMS) mass sensors for various industrial and consumer applications. Founded in 2017 and headquartered in the United Kingdom, the company fabricates its devices on silicon wafers, utilizing a thin film of piezoelectric material that resonates to detect mass changes accurately. These sensors are capable of measuring mass down to the femtogram range and can simultaneously monitor temperature with a resolution of 0.2 °C. Their small size and low power consumption make them suitable for diverse applications, including thin film metrology, particulate monitoring, and gas detection. Additionally, the surface of the sensors can be functionalized to selectively detect specific targets, enhancing their versatility in detecting harmful compounds in various environments, such as homes and workplaces.
Bond180
Seed Round in 2020
Bond180 Limited is a fintech company based in London that focuses on providing technology solutions within the primary debt capital markets. Established in 2019, the company has developed a digital platform that includes a demand management system (DMS) designed to enhance the market-facing activities of institutional investors through improved data and analytics. Additionally, Bond180 offers 180Match, a reverse enquiry engine that facilitates streamlined communication between buyers and sellers in the debt market. The firm also operates an issue administration network, which provides digital asset issuance and administration services to the sell-side. By offering these innovative tools, Bond180 aims to help institutional investors efficiently identify value and source assets for their portfolios.
Colorifix
Series A in 2020
Colorifix Limited is a biotechnology company based in Norwich, United Kingdom, that specializes in innovative textile dyeing services using entirely biological methods. Founded in 2015, Colorifix has developed a unique approach to produce, deposit, and fix pigments onto textiles through synthetic biology. This process utilizes natural colorants derived from organisms such as microbes, plants, and insects, as well as agricultural by-products like sugar molasses, to create safe and environmentally friendly dyes. By eliminating harsh chemicals commonly used in traditional dyeing processes, Colorifix significantly reduces water consumption and pollution, contributing to a more sustainable textile industry. The company’s technological advancements have attracted investment from various stakeholders, supporting its ongoing expansion efforts.
PharmEnable
Seed Round in 2020
PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that was incorporated in 2016. The company specializes in using medicinal chemistry and artificial intelligence to design small molecule drugs. PharmEnable has developed a rapid and cost-effective method for identifying improved chemical starting points, which aims to enhance the discovery of essential new medicines.
Qkine
Series A in 2020
Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in manufacturing high-purity, animal-free growth factors, cytokines, and complex proteins. The company leverages proprietary protein production processes developed at the University of Cambridge, along with advanced protein engineering techniques, to create unique products that address key challenges in the stem cell, organoid, regenerative medicine, and cultivated meat sectors. Qkine's product line includes innovative offerings such as tag-free thermostable FGF-2, the first animal-free TGF beta 1 for chemically defined stem cell media, and animal-free HGF. With an active research and development pipeline and a commitment to quality, Qkine is ISO 9001:2015 certified, ensuring that it provides high-purity, bioactive proteins to support scientific advancements in life sciences.
Flusso
Series A in 2020
Flusso Ltd, established in 2016 and located in Cambridge, United Kingdom, specializes in the development and manufacturing of flow sensor solutions. The company focuses on semiconductor technology, providing mass flow and air velocity sensors tailored for diverse industrial applications. Flusso's innovative sensor products are designed to meet proprietary technology needs across various sectors.
Xampla
Seed Round in 2020
Xampla Ltd is a cleantech company based in Cambridge, United Kingdom, that specializes in developing plant protein-based materials as sustainable alternatives to traditional plastics and microplastics. Founded in 2018, Xampla produces a variety of products, including microcapsules, films, coatings, and beads, which are designed for use in sectors such as food, cosmetics, household products, animal feed, packaging, and medical applications. All materials are biodegradable and biocompatible, made without synthetic ingredients, allowing clients to create environmentally friendly products that minimize pollution.
Porotech
Seed Round in 2020
Porotech is a spin-out from the University of Cambridge that specializes in the development of gallium nitride (GaN) semiconductor technologies. Co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver, the company focuses on creating energy-efficient wide-bandgap semiconductors through advanced material technologies. By harnessing the potential of GaN, Porotech aims to enhance the efficiency of light-emitting diodes and various electronic devices, thereby contributing to innovations in the electronics industry.
Kalium Health
Seed Round in 2020
Kalium Health Ltd is a company focused on improving kidney care through innovative medical technology. Based in Cambridge, United Kingdom, it designs and manufactures a finger-prick blood test specifically for measuring blood potassium concentration. This test aims to facilitate early treatment for patients, reducing the complications and costs associated with traditional testing methods. By leveraging advanced electrolyte sensing technology, Kalium Health provides patients with accurate, real-time data essential for managing cardiorenal diseases. The company’s first product addresses a significant risk in kidney disease, a condition that imposes substantial financial burdens on healthcare systems. With a clear regulatory pathway and a targeted market strategy, Kalium Health is poised to transform patient care and enhance outcomes for millions affected by kidney disease.
AudioTelligence
Series A in 2020
AudioTelligence Ltd is a company based in Cambridge, United Kingdom, founded in 2017, that specializes in real-time audio processing technology aimed at improving automatic speech recognition (ASR) systems. The company utilizes an innovative approach known as blind audio signal separation, which allows it to effectively distinguish target voices from background noise without relying on high-quality microphones. This technology enhances the clarity and intelligibility of audio, making it easier for humans and voice-activated devices to engage in conversations despite challenging acoustic environments. AudioTelligence's solutions outperform traditional methods such as beamforming and spectral masking, positioning the company as a leader in the field of audio enhancement.
Tenyks
Pre Seed Round in 2020
Tenyks is a spin-out from the University of Cambridge focused on enhancing the interaction between humanity and artificial intelligence, particularly in the realm of computer vision. The company has developed a monitoring and validation platform aimed at machine learning engineers, enabling them to build more reliable software swiftly. Through this platform, users can validate, test, and monitor model behavior, identify common failure patterns, and understand the reasons behind shifts in data distribution. Tenyks’ technology is grounded in extensive research in Explainable AI, comprising contributions from two PhD and one Master theses, which underpins its capability to reduce the amount of labeled data needed for high-performance outcomes. This approach allows AI developers to address algorithmic issues efficiently, thereby accelerating the development of robust machine learning operations.
Cambridge Energy Partners
Seed Round in 2020
Cambridge Energy Partners is a manufacturer of mobile solar trackers for the global commercial and industrial sector. Their trackers look and perform like traditional solar when installed, but arrive at site in prefabricated units, ready for fast deployment and connection (4x faster than traditional installations). Their product is a truly scalable mobile solar tracker, and offers users 'big solar' quality, while also reducing stranded asset risk - enabling the owner to deploy the asset multiple times over its 25-year useful life.
Spirea
Pre Seed Round in 2019
Spirea Ltd. is a healthcare technology company based in Harrogate, United Kingdom, that specializes in developing antibody drug conjugates (ADCs) for cancer treatment. Founded in 2015, Spirea has created a smart polymer platform designed for the controlled delivery of drug combinations, thereby maximizing the clinical efficacy of therapies. The company's innovative approach to ADCs allows for a greater amount of drug payload to be specifically targeted to tumor cells, resulting in enhanced therapeutic effects while significantly minimizing side effects. This development enables healthcare providers to offer well-tolerated treatment options for a variety of cancers, ultimately aiming to improve the quality of life for patients.
Porotech
Seed Round in 2019
Porotech is a spin-out from the University of Cambridge that specializes in the development of gallium nitride (GaN) semiconductor technologies. Co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver, the company focuses on creating energy-efficient wide-bandgap semiconductors through advanced material technologies. By harnessing the potential of GaN, Porotech aims to enhance the efficiency of light-emitting diodes and various electronic devices, thereby contributing to innovations in the electronics industry.
Nu Quantum
Pre Seed Round in 2019
Nu Quantum Ltd is a company focused on developing quantum photonics hardware and infrastructure essential for scaling quantum computers. Founded in 2018 and based in Cambridge, United Kingdom, the company specializes in creating solutions that interconnect quantum computing cores into large distributed clusters. Its offerings include photon sources and detectors, as well as systems for quantum cryptography that enable secure key exchanges. Nu Quantum is also engaged in producing nano-engineered materials that facilitate light generation at the quantum level and ultra-sensitive light detection. By partnering with leading quantum computing companies, governments, and research institutions, Nu Quantum aims to advance the development of entangled qubit networks and accelerate the creation of multi-core quantum supercomputers and quantum data centers.
Bond180
Pre Seed Round in 2019
Bond180 Limited is a fintech company based in London that focuses on providing technology solutions within the primary debt capital markets. Established in 2019, the company has developed a digital platform that includes a demand management system (DMS) designed to enhance the market-facing activities of institutional investors through improved data and analytics. Additionally, Bond180 offers 180Match, a reverse enquiry engine that facilitates streamlined communication between buyers and sellers in the debt market. The firm also operates an issue administration network, which provides digital asset issuance and administration services to the sell-side. By offering these innovative tools, Bond180 aims to help institutional investors efficiently identify value and source assets for their portfolios.
PredictImmune
Series B in 2019
PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. The company's flagship product, PredictSURE IBD, is a diagnostic tool that evaluates patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis. This test utilizes a small blood sample to identify patients at diagnosis who are at risk of severe, relapsing disease, thereby enabling healthcare providers to recommend early biologic therapy to those who would benefit most. By providing crucial prognostic information, PredictImmune aims to enhance treatment decision-making for physicians and improve outcomes for patients suffering from these conditions. The company's research is rooted in leading studies from Cambridge University, reflecting its commitment to advancing personalized medicine in the field of inflammatory bowel disease.
Paragraf
Series A in 2019
Paragraf Ltd. is a UK-based company established in 2015, specializing in the development and production of graphene-based electronic devices and materials. The company employs contamination-free technology to create high-purity graphene products, which are designed to enhance the performance of various electronic applications. Paragraf's innovations include devices for green energy generation, such as solar photovoltaic cells, as well as advanced sensors for monitoring environmental and health-related parameters. These products aim to optimize process and quality control across industries including electronics, energy, healthcare, and agriculture. By leveraging graphene's unique properties, Paragraf seeks to significantly impact the electronics industry and contribute to advancements in automation and disease research.
Riverlane
Seed Round in 2019
Riverlane is a business focused on developing quantum computing software and engineering instruments to enhance the performance of quantum computers. The company collaborates with quantum computer manufacturers to create essential hardware and software tools that address the challenges posed by unstable qubits and system defects. By designing an ultra-low latency quantum operating system, Riverlane accelerates quantum-classical hybrid algorithms, thereby advancing hardware research and development. Their algorithms are specifically engineered to optimize the utilization of the complete quantum computing stack, helping hardware partners mitigate the system errors that currently hinder the effectiveness of quantum computers. Through these innovative solutions, Riverlane aims to transform experimental quantum technologies into viable commercial products.
Qkine
Seed Round in 2019
Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in manufacturing high-purity, animal-free growth factors, cytokines, and complex proteins. The company leverages proprietary protein production processes developed at the University of Cambridge, along with advanced protein engineering techniques, to create unique products that address key challenges in the stem cell, organoid, regenerative medicine, and cultivated meat sectors. Qkine's product line includes innovative offerings such as tag-free thermostable FGF-2, the first animal-free TGF beta 1 for chemically defined stem cell media, and animal-free HGF. With an active research and development pipeline and a commitment to quality, Qkine is ISO 9001:2015 certified, ensuring that it provides high-purity, bioactive proteins to support scientific advancements in life sciences.
PolyProx
Seed Round in 2019
PolyProx Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2018. It focuses on researching and developing innovative drug therapies aimed at treating cancer and neurodegenerative diseases. The company's flagship product, Polyproxin, utilizes engineered proteins that selectively target tumor cells. This mechanism activates the natural degradation processes within the cells, allowing for the removal of disease-causing proteins. By employing this novel approach, PolyProx aims to provide effective treatment options for cancer patients, potentially improving their outcomes and quality of life.
Sano Genetics
Seed Round in 2019
Sano Genetics Limited is a health technology company based in Cambridge, United Kingdom, that operates a user-centric genetic data-sharing platform. Founded in 2017, the company enables individuals to contribute their genetic and health data for research purposes, thereby advancing personalized medicine and scientific understanding. It provides researchers with tools to analyze user-consented data, facilitating recruitment for studies and clinical trials. The platform supports research on a variety of genetic conditions and human traits, including common disorders such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. By allowing participants to share their genetic information, Sano Genetics aims to enhance the development of new treatments and cures in the field of medicine.
Morphogen-IX
Series B in 2018
Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing novel treatments for pulmonary arterial hypertension (PAH), a serious condition affecting lung blood vessels that can lead to heart failure. Founded in 2015 by Index Ventures, the company is exploring the therapeutic potential of bone morphogenetic proteins (BMPs), particularly BMP9 and BMP10, which have shown promise in enhancing BMPR-II receptor signaling in endothelial cells. This signaling is crucial for reversing the effects of PAH, as compromised BMPR-II signaling is central to the disease's pathology. Current PAH treatments primarily address symptoms, and effective long-term solutions are limited, often requiring risky lung transplants. Morphogen-IX employs a semi-virtual business model, leveraging a network of experienced professionals in drug discovery while maintaining operational efficiency through outsourcing. The company's founders are recognized experts in both PAH and BMP research, positioning Morphogen-IX to potentially transform the treatment landscape for this life-limiting disease.
Colorifix
Series A in 2018
Colorifix Limited is a biotechnology company based in Norwich, United Kingdom, that specializes in innovative textile dyeing services using entirely biological methods. Founded in 2015, Colorifix has developed a unique approach to produce, deposit, and fix pigments onto textiles through synthetic biology. This process utilizes natural colorants derived from organisms such as microbes, plants, and insects, as well as agricultural by-products like sugar molasses, to create safe and environmentally friendly dyes. By eliminating harsh chemicals commonly used in traditional dyeing processes, Colorifix significantly reduces water consumption and pollution, contributing to a more sustainable textile industry. The company’s technological advancements have attracted investment from various stakeholders, supporting its ongoing expansion efforts.
Healthera
Series A in 2018
Healthera operates a comprehensive healthcare marketplace in the UK, connecting patients with medicines, healthcare services, and products through a vast digital platform that includes both national pharmacy chains and independent providers. The company's technology facilitates quicker medicine delivery and personalized medical care tailored to individual needs. By reinventing the pharmacy operating model, Healthera enhances patient communication, encourages cross-sales, and fosters customer loyalty. The company is dedicated to digitizing and automating primary care processes, which improves prescribing efficiency and the overall patient experience while minimizing waste for the NHS. Partnering with over 1,000 pharmacies and clinical commissioning groups, Healthera reaches more than 20 million individuals. Its technology is accredited by NHS Digital, positioning Healthera as one of the fastest-growing digital health firms in Europe. Headquartered in Cambridge, the company boasts a diverse international team committed to improving healthcare delivery through human-centered technology.
Silicon Microgravity
Venture Round in 2018
Silicon Microgravity Limited specializes in the development of advanced sensor devices tailored for the oil and gas sector. Founded in 2014 as a spin-out from Cambridge University, the company leverages sensor technology originally developed through a collaboration with BP. This technology enables the recording of gravity data at high sensitivities and seismic data at ultra-low frequencies, significantly enhancing the management of oil and gas reservoirs. By using microelectromechanical system sensors, Silicon Microgravity transforms the measurement of densities deep within reservoirs from boreholes. Additionally, its technology finds applications in navigation, guidance, and stabilization for various intelligent systems across commercial, industrial, and military sectors. The innovations provided by Silicon Microgravity aim to improve efficiency and reduce costs for clients while supporting their social, safety, and environmental objectives.
Sorex Sensors
Seed Round in 2018
Sorex Sensors Limited specializes in the design and manufacture of film bulk acoustic resonator (FBAR) technology-based micro-electro-mechanical system (MEMS) mass sensors for various industrial and consumer applications. Founded in 2017 and headquartered in the United Kingdom, the company fabricates its devices on silicon wafers, utilizing a thin film of piezoelectric material that resonates to detect mass changes accurately. These sensors are capable of measuring mass down to the femtogram range and can simultaneously monitor temperature with a resolution of 0.2 °C. Their small size and low power consumption make them suitable for diverse applications, including thin film metrology, particulate monitoring, and gas detection. Additionally, the surface of the sensors can be functionalized to selectively detect specific targets, enhancing their versatility in detecting harmful compounds in various environments, such as homes and workplaces.
Cambridge Touch Technologies
Series A in 2018
Cambridge Touch Technologies, Ltd. specializes in developing innovative touch technology for smart devices, including smartphones, tablets, and applications in automotive and industrial sectors. The company's flagship offering, UltraTouch, integrates a proprietary artificial intelligence engine with advanced piezoelectric force film to create an all-in-one touch and force sensor architecture. This technology not only enhances the user experience by enabling three-dimensional touch capabilities but also offers superior functionality at a lower cost. UltraTouch is designed to be scalable, accommodating various device sizes and shapes, including curved and foldable formats, thereby ensuring versatility in application across multiple industries.
PhoreMost
Series A in 2018
PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, focused on identifying new druggable targets for cancer and other unmet diseases. Since its incorporation in 2014, the company has developed Site-Seeker, a platform that uncovers cryptic druggable sites within the human genome and connects them to therapeutic functions in live-cell contexts. This innovative approach allows PhoreMost to design small molecule drugs based on functionally validated protein fragments. By collaborating with a global network of academic and industrial partners, the company aims to bring novel targeted therapies to market more efficiently, ultimately benefiting patients through cost savings and the development of first-in-class drug discovery programs for potential licensing to pharmaceutical companies.
Qkine
Seed Round in 2018
Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in manufacturing high-purity, animal-free growth factors, cytokines, and complex proteins. The company leverages proprietary protein production processes developed at the University of Cambridge, along with advanced protein engineering techniques, to create unique products that address key challenges in the stem cell, organoid, regenerative medicine, and cultivated meat sectors. Qkine's product line includes innovative offerings such as tag-free thermostable FGF-2, the first animal-free TGF beta 1 for chemically defined stem cell media, and animal-free HGF. With an active research and development pipeline and a commitment to quality, Qkine is ISO 9001:2015 certified, ensuring that it provides high-purity, bioactive proteins to support scientific advancements in life sciences.
Paragraf
Seed Round in 2018
Paragraf Ltd. is a UK-based company established in 2015, specializing in the development and production of graphene-based electronic devices and materials. The company employs contamination-free technology to create high-purity graphene products, which are designed to enhance the performance of various electronic applications. Paragraf's innovations include devices for green energy generation, such as solar photovoltaic cells, as well as advanced sensors for monitoring environmental and health-related parameters. These products aim to optimize process and quality control across industries including electronics, energy, healthcare, and agriculture. By leveraging graphene's unique properties, Paragraf seeks to significantly impact the electronics industry and contribute to advancements in automation and disease research.
Cytora
Series A in 2017
Cytora is a London-based company founded in 2014 that specializes in a configurable platform designed for commercial insurers to enhance their risk processing capabilities. The platform digitizes incoming risks and enriches them with both internal and external data sources. It evaluates these risks using various rules related to appetite and priority before directing them to downstream systems for either automated or manual underwriting. By leveraging artificial intelligence, Cytora's platform learns the patterns of different risks and loss outcomes over time, allowing insurers to assign a rank, score, and price to each property and organization. This approach aims to improve risk selection, pricing accuracy, and overall efficiency in underwriting processes.
PredictImmune
Series A in 2017
PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. The company's flagship product, PredictSURE IBD, is a diagnostic tool that evaluates patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis. This test utilizes a small blood sample to identify patients at diagnosis who are at risk of severe, relapsing disease, thereby enabling healthcare providers to recommend early biologic therapy to those who would benefit most. By providing crucial prognostic information, PredictImmune aims to enhance treatment decision-making for physicians and improve outcomes for patients suffering from these conditions. The company's research is rooted in leading studies from Cambridge University, reflecting its commitment to advancing personalized medicine in the field of inflammatory bowel disease.
Z Factor
Series A in 2017
Z Factor Limited is a drug discovery company established in 2015, focusing on developing therapeutic agents for alpha-1-antitrypsin deficiency. Founded through a collaboration between Index Ventures and the University of Cambridge, the company aims to design innovative treatments that correct the misfolding of the Z variant of alpha-1-antitrypsin. This condition currently has limited treatment options, primarily relying on lung or liver transplantation and augmentation therapy. Z Factor's mission addresses a significant unmet medical need by working to create effective alternatives for patients suffering from this deficiency.
Focal Point Positioning
Series B in 2017
Focal Point Positioning Ltd. specializes in advanced positioning technologies, focusing on smartphone-based sensor fusion, machine learning, and signal processing to enhance satellite positioning capabilities in previously inaccessible areas. Founded in 2015 and based in Cambridge, United Kingdom, the company offers consultancy services in positioning, navigation, and timing, addressing challenges related to GNSS, GPS-denied environments, and emerging quantum sensing technologies. Focal Point has developed two key products: S-GNSS, which significantly enhances the sensitivity and accuracy of GPS receivers for indoor and remote tracking, and D-Tail, which utilizes existing smartphone and wearable device sensors for precise three-dimensional user tracking. The company serves a diverse range of industries, including defense, security, aerospace, autonomy, telecom, retail, logistics, and emergency services. Dr. Ramsey Faragher, the founder, is a recognized expert in GNSS-denied positioning, with a distinguished background in developing innovative technologies for military and space applications.
Cytora
Series A in 2017
Cytora is a London-based company founded in 2014 that specializes in a configurable platform designed for commercial insurers to enhance their risk processing capabilities. The platform digitizes incoming risks and enriches them with both internal and external data sources. It evaluates these risks using various rules related to appetite and priority before directing them to downstream systems for either automated or manual underwriting. By leveraging artificial intelligence, Cytora's platform learns the patterns of different risks and loss outcomes over time, allowing insurers to assign a rank, score, and price to each property and organization. This approach aims to improve risk selection, pricing accuracy, and overall efficiency in underwriting processes.
Polypharmakos
Series A in 2017
Polypharmakos Limited, founded in 2016 and based in Witney, United Kingdom, focuses on discovering and developing new antimicrobials derived from plants, fungi, and other natural sources. The company's mission is to tackle the growing global crisis of antimicrobial resistance (AMR) by providing innovative, chemical-free drug treatments. Its products serve various sectors, including pharmaceuticals, consumer health, and agri-tech, aiming to address the urgent need for effective antimicrobial solutions in an era of increasing resistance to conventional treatments.
Cambridge Touch Technologies
Series A in 2016
Cambridge Touch Technologies, Ltd. specializes in developing innovative touch technology for smart devices, including smartphones, tablets, and applications in automotive and industrial sectors. The company's flagship offering, UltraTouch, integrates a proprietary artificial intelligence engine with advanced piezoelectric force film to create an all-in-one touch and force sensor architecture. This technology not only enhances the user experience by enabling three-dimensional touch capabilities but also offers superior functionality at a lower cost. UltraTouch is designed to be scalable, accommodating various device sizes and shapes, including curved and foldable formats, thereby ensuring versatility in application across multiple industries.
Carrick Therapeutics
Series A in 2016
Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.
PervasID
Series A in 2016
PervasID Limited, founded in 2011 and based in Cambridge, United Kingdom, specializes in the development of wide area passive RFID systems. The company emerged from research conducted at the University of Cambridge and focuses on providing location capabilities based on the EPC Class1 Gen2 standard. PervasID's technology employs fixed ultra-high frequency RFID to accurately detect passive tags over long distances, facilitating enhanced visibility into goods, assets, and people. Its innovative systems are designed to serve various industries, including retail, healthcare, supply chain and logistics, and aviation. The technology has been successfully deployed in multiple field trials, demonstrating its reliability and effectiveness in streamlining processes across diverse markets.
Fluidic Analytics
Series B in 2016
Fluidic Analytics Limited, established in 2013 as a spin-out from the University of Cambridge's Department of Chemistry, specializes in designing and manufacturing advanced tools for protein characterization. The company offers innovative products, including Fluidity One and Fluidity One-W, which facilitate in-solution sizing and quantification of native proteins, as well as high-sensitivity analysis of protein interactions and kinetics. These tools are essential for applications such as assessing protein quality, interactions, and aggregation. Targeting scientists, clinics, and healthcare providers, Fluidic Analytics aims to enhance the understanding of protein behavior and function, paralleling the transformative impact of DNA sequencing in biology. With a commitment to accessibility and collaboration, the company strives to create a community that fosters open exchange and empowers users with complete ownership of their data. By combining cutting-edge technology with a dedicated team, Fluidic Analytics is positioned to advance the field of protein science significantly.
Cambridge Innovation Capital
Venture Round in 2016
Cambridge Innovation Capital, established in 2013, is a venture capital firm based in Cambridge, UK. It specializes in early-stage investments, focusing on life sciences and technology companies with affiliations to the University of Cambridge or the Cambridge Cluster. The firm invests in a wide range of sectors, including healthcare, therapeutics, medtech, digital health, genomics, and emerging technologies such as AI, IoT, and quantum technologies. Cambridge Innovation Capital typically invests up to £19 million per company, providing long-term equity finance to support the growth and commercial development of innovative businesses. As a preferred investor for the University of Cambridge, the firm has access to a robust pipeline of investment opportunities within the ecosystem. Since its inception, Cambridge Innovation Capital has raised £275 million to fund disruptive, deep-tech businesses.
Healthera
Seed Round in 2016
Healthera operates a comprehensive healthcare marketplace in the UK, connecting patients with medicines, healthcare services, and products through a vast digital platform that includes both national pharmacy chains and independent providers. The company's technology facilitates quicker medicine delivery and personalized medical care tailored to individual needs. By reinventing the pharmacy operating model, Healthera enhances patient communication, encourages cross-sales, and fosters customer loyalty. The company is dedicated to digitizing and automating primary care processes, which improves prescribing efficiency and the overall patient experience while minimizing waste for the NHS. Partnering with over 1,000 pharmacies and clinical commissioning groups, Healthera reaches more than 20 million individuals. Its technology is accredited by NHS Digital, positioning Healthera as one of the fastest-growing digital health firms in Europe. Headquartered in Cambridge, the company boasts a diverse international team committed to improving healthcare delivery through human-centered technology.
8Power
Seed Round in 2016
8Power Limited specializes in the manufacturing of autonomous sensor systems tailored for various sectors, including automotive, transportation, civil engineering, industrial equipment, and utility infrastructure. The company has developed wireless sensor technology that provides real-time condition monitoring data and analytics for industrial applications. This technology enables clients to monitor the performance of their assets, such as pumps, motors, and gearboxes, across numerous remote locations. By offering a cost-effective solution, 8Power facilitates easy installation and effective machine condition monitoring, serving industries such as water and waste treatment, manufacturing, and oil and gas.
Psyomics
Series A in 2016
Psyomics is engaged in the development of proteomic diagnostics aimed at improving the early diagnosis and treatment outcomes for individuals with neuropsychiatric disorders. The company offers a web-based assessment triage system that integrates digital profiling with advancements in biological research to enhance diagnostic accuracy. This approach assists primary care practitioners in effectively managing their patients' mental health needs by replicating a psychiatric assessment at the initial point of contact. By doing so, Psyomics facilitates improved recovery outcomes for patients suffering from mental health disorders.
DefiniGEN
Series B in 2016
DefiniGEN Limited specializes in providing human cell products for the life science and drug discovery sectors, focusing on applications in predictive toxicology, metabolic diseases, and regenerative medicine. The company’s product offerings include wild-type human hepatocytes and pancreatic cells for research in diabetes, alongside disease-modelled cells for conditions such as glycogen storage disease and hypercholesterolemia. DefiniGEN leverages its advanced stem cell production platform, developed at the University of Cambridge, to create high-functionality cell types that enhance drug discovery processes. The company also offers a range of services, including custom cell production, gene-editing, and diabetes compound profiling, catering primarily to pharmaceutical companies. Established in 2011 and based in Cambridge, UK, DefiniGEN builds on its strong intellectual property foundation, including expertise in induced pluripotent stem cell technology.
ROADMap Systems
Series A in 2016
ROADMap Systems Limited, based in Cambridge, United Kingdom, specializes in advanced technology solutions for fiber optic communication networks. Founded in 2013, the company focuses on wavelength selective switch (WSS) technology, which is essential for creating reconfigurable optical add/drop multiplexers (ROADMs). By leveraging four patents licensed from the Cambridge Centre for Advanced Photonics and Electronics, ROADMap addresses critical challenges faced by network operators, including the need to enhance capacity to meet growing internet data demands, manage operational and capital expenditure pressures, and adapt to rapidly changing service requirements. Their innovative solutions enable highly flexible optical switching that can operate at the wavelength level, accommodating next-generation data rates that conventional switch architectures are unable to support.
Cambridge Epigenetix
Series B in 2016
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.
Morphogen-IX
Series A in 2016
Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing novel treatments for pulmonary arterial hypertension (PAH), a serious condition affecting lung blood vessels that can lead to heart failure. Founded in 2015 by Index Ventures, the company is exploring the therapeutic potential of bone morphogenetic proteins (BMPs), particularly BMP9 and BMP10, which have shown promise in enhancing BMPR-II receptor signaling in endothelial cells. This signaling is crucial for reversing the effects of PAH, as compromised BMPR-II signaling is central to the disease's pathology. Current PAH treatments primarily address symptoms, and effective long-term solutions are limited, often requiring risky lung transplants. Morphogen-IX employs a semi-virtual business model, leveraging a network of experienced professionals in drug discovery while maintaining operational efficiency through outsourcing. The company's founders are recognized experts in both PAH and BMP research, positioning Morphogen-IX to potentially transform the treatment landscape for this life-limiting disease.
Silicon Microgravity
Seed Round in 2016
Silicon Microgravity Limited specializes in the development of advanced sensor devices tailored for the oil and gas sector. Founded in 2014 as a spin-out from Cambridge University, the company leverages sensor technology originally developed through a collaboration with BP. This technology enables the recording of gravity data at high sensitivities and seismic data at ultra-low frequencies, significantly enhancing the management of oil and gas reservoirs. By using microelectromechanical system sensors, Silicon Microgravity transforms the measurement of densities deep within reservoirs from boreholes. Additionally, its technology finds applications in navigation, guidance, and stabilization for various intelligent systems across commercial, industrial, and military sectors. The innovations provided by Silicon Microgravity aim to improve efficiency and reduce costs for clients while supporting their social, safety, and environmental objectives.
Cytora
Seed Round in 2015
Cytora is a London-based company founded in 2014 that specializes in a configurable platform designed for commercial insurers to enhance their risk processing capabilities. The platform digitizes incoming risks and enriches them with both internal and external data sources. It evaluates these risks using various rules related to appetite and priority before directing them to downstream systems for either automated or manual underwriting. By leveraging artificial intelligence, Cytora's platform learns the patterns of different risks and loss outcomes over time, allowing insurers to assign a rank, score, and price to each property and organization. This approach aims to improve risk selection, pricing accuracy, and overall efficiency in underwriting processes.
Quethera
Seed Round in 2015
Quethera Limited is a gene therapy company based in Canterbury, United Kingdom, founded in 2013. The company specializes in developing innovative treatments for glaucoma and other ophthalmic diseases, particularly aimed at reducing progressive visual loss associated with these conditions. Quethera collaborates with leading experts in the field of glaucoma to design and conduct clinical trials that evaluate the efficacy and safety of its novel therapies, especially for patients who experience accelerated visual field loss. With a strong foundation in gene therapeutic design and development, Quethera is advancing its research pipeline from preclinical testing into clinical development, striving to enhance treatment options for patients suffering from common blinding eye diseases. As of August 2018, Quethera operates as a subsidiary of Astellas Pharma Inc.
Focal Point Positioning
Seed Round in 2015
Focal Point Positioning Ltd. specializes in advanced positioning technologies, focusing on smartphone-based sensor fusion, machine learning, and signal processing to enhance satellite positioning capabilities in previously inaccessible areas. Founded in 2015 and based in Cambridge, United Kingdom, the company offers consultancy services in positioning, navigation, and timing, addressing challenges related to GNSS, GPS-denied environments, and emerging quantum sensing technologies. Focal Point has developed two key products: S-GNSS, which significantly enhances the sensitivity and accuracy of GPS receivers for indoor and remote tracking, and D-Tail, which utilizes existing smartphone and wearable device sensors for precise three-dimensional user tracking. The company serves a diverse range of industries, including defense, security, aerospace, autonomy, telecom, retail, logistics, and emergency services. Dr. Ramsey Faragher, the founder, is a recognized expert in GNSS-denied positioning, with a distinguished background in developing innovative technologies for military and space applications.
Reduse
Series A in 2015
Reduse Limited provides print removal services from paper using laser technology. Founded in 2015 by David Leal-Ayala, Hidde-Jan Lemstra, and Stuart Evans, the company is headquartered in Cambridge, United Kingdom. Reduse focuses on innovative solutions for recycling and reusing paper materials, offering a sustainable alternative to traditional methods of handling printed paper waste.
Fluidic Analytics
Series A in 2014
Fluidic Analytics Limited, established in 2013 as a spin-out from the University of Cambridge's Department of Chemistry, specializes in designing and manufacturing advanced tools for protein characterization. The company offers innovative products, including Fluidity One and Fluidity One-W, which facilitate in-solution sizing and quantification of native proteins, as well as high-sensitivity analysis of protein interactions and kinetics. These tools are essential for applications such as assessing protein quality, interactions, and aggregation. Targeting scientists, clinics, and healthcare providers, Fluidic Analytics aims to enhance the understanding of protein behavior and function, paralleling the transformative impact of DNA sequencing in biology. With a commitment to accessibility and collaboration, the company strives to create a community that fosters open exchange and empowers users with complete ownership of their data. By combining cutting-edge technology with a dedicated team, Fluidic Analytics is positioned to advance the field of protein science significantly.
Cambridge Epigenetix
Series A in 2014
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.